Fig. 5

MEKi does not affect IFNAR signaling and its negative feedback loop. a Immunoblot analysis (with anti-pSTAT1, anti-STAT1 and anti-α-tubulin) of AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). b Immunoblot analysis (with anti-pSTAT2, anti-STAT2 and anti-α-tubulin) of AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). c qRT-PCR analysis of SOCS1 mRNA in AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). d qRT-PCR analysis of USP18 mRNA in AECs pretreated DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). e qRT-PCR analysis of SOCS3 mRNA in AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). a and b are representative immunoblots (n = 6). Each symbol () represents a donor and the horizontal bars represent the grand median in c, d, e (n = 6). Statistical analysis was performed with the Wilcoxon signed-rank test. * p < 0.05 indicates statistical significance